Welcome to the international HTA database

Showing [23806 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2016	Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS)	[Effectiveness and safety of irreversible electroporation in the treatment of of cancers of the liver and pancreas. Systematic review. Update]
2016	National Institute for Health and Care Excellence (NICE)	Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia. NICE technology appraisal guidance 385
2016	Belgian Health Care Knowledge Centre (KCE)	Economic evaluation of novel direct acting antiviral (DAA) treatment strategies for chronic hepatitis C
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Cognitive processing therapy for post-traumatic stress disorder: a systematic review and meta-analysis
2016	National Institute for Health and Care Excellence (NICE)	Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis. NICE technology appraisal guidance 386
2016	NIHR Health Technology Assessment programme	A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Fundus autofluorescence for the diagnosis of retinopathies
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	DNA mismatch repair deficiency tumour testing for patients with colorectal cancer: a health technology assessment
2016	National Institute for Health and Care Excellence (NICE)	Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. NICE technology appraisal guidance 387
2016	NIHR Health Technology Assessment programme	A multicentre, randomised controlled trial comparing the clinical effectiveness and cost-effectiveness of early nutritional support via the parenteral versus the enteral route in critically ill patients (CALORIES)
2016	Agency for Healthcare Research and Quality (AHRQ)	Disparities within serious mental illness
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Calcium dobesilate for the treatment of chronic venous insufficiency
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Capnography for monitoring end-tidal CO2 in hospital and pre-hospital settings: a health technology assessment
2016	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Relevance of adjusting the D-dimer test positivity threshold according to age in patients at low risk of venous thromboembolic events]
2016	National Institute for Health and Care Excellence (NICE)	Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction. NICE technology appraisal guidance 388
2016	NIHR Health Technology Assessment programme	A systematic review of the clinical effectiveness and cost-effectiveness of pharmacological and psychological interventions for the management of obsessive-compulsive disorder in children/adolescents and adults
2016	Health Quality Ontario (HQO)	Composite tissue transplant of hand or arm: a health technology assessment
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	lntravitreal glucocorticoids in posterior retina conditions
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Monitoring for atrial fibrillation in discharged stroke and transient ischemic attack patients: a clinical and cost-effectiveness analysis and review of patient preferences
2016	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Blood conservation strategies in cardiac surgery: the thromboelastogram and rotational thromboelastometer for monitoring hemostasis in cardiac surgery]
2016	National Institute for Health and Care Excellence (NICE)	Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer. NICE technology appraisal guidance 389
2016	NIHR Health Technology Assessment programme	Comparison Of iNfliximab and ciclosporin in Steroid Resistant Ulcerative Colitis: pragmatic randomised Trial and economic evaluation (CONSTRUCT)
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Sutureless aortic valve replacement (SuAVR) for aortic stenosis
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Endoscopic ultrasound elastography
2016	Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval)	[Evaluation of technologies allowing the induction of therapeutic hypothermia in patients who have suffered a cardiac arrest]
2016	National Institute for Health and Care Excellence (NICE)	Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes. NICE technology appraisal guidance 390
2016	NIHR Health Technology Assessment programme	PROMISE: first-trimester progesterone therapy in women with a history of unexplained recurrent miscarriages - a randomised, double-blind, placebo-controlled, international multicentre trial and economic evaluation
2016	NIHR Health Technology Assessment programme	The feasibility of determining the effectiveness and cost-effectiveness of medication organisation devices compared with usual care for older people in a community setting: systematic review, stakeholder focus groups and feasibility randomised controlled trial
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Implantable Left Ventricular Assist Device (LVAD) in addition to guideline directed medical therapy (GDMT) in end stage heart failure
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Endobutton® and Retrobutton® for femoral fixation of the anterior cruciate ligament graft
2016	Health Sciences Institute in Aragon (IACS)	Electronic prosthesis for Dysphemia. Effectiveness and safety of electronic devices in improving the fluency of stuttering
2016	National Institute for Health and Care Excellence (NICE)	Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel. NICE technology appraisal guidance 391
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	Transcatheter implantable devices for mitral valve repair in adults with chronic mitral valve regurgitation
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Nivolumab for the treatment of renal-cell carcinoma
2016	Health Sciences Institute in Aragon (IACS)	Effectiveness, security and economic evaluation of the screening for cryptorchidism
2016	National Institute for Health and Care Excellence (NICE)	Adalimumab for treating moderate to severe hidradenitis suppurativa. NICE technology appraisal guidance 392
2016	NIHR Health Technology Assessment programme	A cost-effectiveness modelling study of strategies to reduce risk of infection following primary hip replacement based on a systematic review
2016	Agenzia nazionale per i servizi sanitari regionali (Agenas)	[Report adaptation: health technology assessment of the different dialysis modalities in Italy]
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Dextrometorphan-quinidine for the treatment of pseudobulbar affect
2016	National Institute for Health and Care Excellence (NICE)	Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 393
2016	Canary Health Service	[Fetal DNA analysis in maternal blood for the detection of trisomies 21, 18 and 13]
2016	NIHR Health Technology Assessment programme	The feasibility of a randomised controlled trial of physiotherapy for adults with joint hypermobility syndrome
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ceritinib (Zykadia) - non-small cell lung cancer: locally advanced or metastatic; anaplastic lymphoma kinase (ALK) positive – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Multiplex PCR panels (FilmArray®) to diagnose infections
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure]
2016	National Institute for Health and Care Excellence (NICE)	Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia. NICE technology appraisal guidance 394
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Fractional exhaled nitric oxygen in asthma patients
2016	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Measurement and monitoring of pulmonary artery pressure via an implanted sensor for treatment optimization in heart failure - Addendum to Commission E15-04]
2016	National Institute for Health and Care Excellence (NICE)	Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer. NICE technology appraisal guidance 395
2016	Canary Health Service	[Spanish society's willingness to pay for a quality-adjusted life year]
2016	NIHR Health Technology Assessment programme	Financial incentives to improve adherence to antipsychotic maintenance medication in non-adherent patients: a cluster randomised controlled trial
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Decitabine (Dacogen) - acute myeloid leukaemia: newly diagnosed de novo or secondary; adult patients of all ages who are not suitable for standard induction chemotherapy
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Extracorporeal shock wave therapy in musculoskeletal disorders
2016	National Institute for Health and Care Excellence (NICE)	Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma. NICE technology appraisal guidance 396
2016	Canary Health Service	[Effectiveness and cost-effectiveness of surveillance programs to prevent hip dislocation in cerebral palsy]
2016	NIHR Health Technology Assessment programme	The Diagnosis of Urinary Tract infection in Young children (DUTY): a diagnostic prospective observational study to derive and validate a clinical algorithm for the diagnosis of urinary tract infection in children presenting to primary care with an acute illness
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Botulinum toxin for sialorrhea
2016	National Institute for Health and Care Excellence (NICE)	Lumacaftorivacaftor for treating cystic fibrosis homozygous for the F508del mutation. NICE technology appraisal guidance 398
2016	Canary Health Service	[Effectiveness, safety and cost-effectiveness of the flash interstitial fluid glucose monitoring system (FreeStyle Libre®) for type 1 and 2 diabetes mellitus]
2016	NIHR Health Technology Assessment programme	CATheter Infections in CHildren (CATCH): a randomised controlled trial and economic evaluation comparing impregnated and standard central venous catheters in children
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) - colorectal cancer: advanced or metastatic; high-level microsatellite instability – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Magnetic resonance neurography to study peripheral neuropathies
2016	National Institute for Health and Care Excellence (NICE)	Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts. NICE technology appraisal guidance 399
2016	Canary Health Service	[Indications, safety, effectiveness and cost-effectiveness of noninvasive brain stimulation in the treatment of mental disorders]
2016	NIHR Health Technology Assessment programme	The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer
2016	NIHR Health Technology Assessment programme	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer
2016	NIHR Public Health Research (PHR) programme	Change in alcohol outlet density and alcohol-related harm to population health (CHALICE): a comprehensive record-linked database study in Wales
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Pembrolizumab (Keytruda) - Hodgkin lymphoma: classical; relapsed or refractory – third and fourth line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	High-dose chemotherapy followed by autologous transplantation of hematopoietic stem cells in patients with recurrent childhood medulloblastoma
2016	National Institute for Health and Care Excellence (NICE)	Nivolumab in combination with ipilimumab for treating advanced melanoma. NICE technology appraisal guidance 400
2016	Canary Health Service	[Extracorporeal membrane oxygenation (ECMO) in patients with advanced heart failure or cardiogenic shock]
2016	NIHR Health Technology Assessment programme	EQUATOR Network
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Quizartinib - acute myeloid leukaemia: relapsed or refractory; FLT3-internal tandem duplication (ITD) positive – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Cannabinoids for refractory epilepsy treatment
2016	National Institute for Health and Care Excellence (NICE)	Bosutinib for previously treated chronic myeloid leukaemia. NICE technology appraisal guidance 401
2016	Canary Health Service	[Patient participation in health technology assessment: methodological manual]
2016	NIHR Health Technology Assessment programme	Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Ribociclib with tamoxifen and goserelin, or a non-steroidal aromatase inhibitor and goserelin - breast cancer: advanced; hormone-receptor positive, human epidermal growth factor receptor 2 (HER2) negative; premenopausal women – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Percutaneous closure of patent foramen ovale for stroke prevention
2016	National Institute for Health and Care Excellence (NICE)	Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin. NICE technology appraisal guidance 402
2016	Canary Health Service	[Safety, clinical effectiveness and cost-effectiveness of stereo-electroencephalography in epilepsy surgery]
2016	NIHR Health Technology Assessment programme	Does therapeutic writing help people with long-term conditions? Systematic review, realist synthesis and economic considerations
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Sapacitabine - acute myeloid leukaemia: patients ≥70 years of age; not candidates for standard intensive therapy – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Activated charcoal for preoperative localization of thyroid cancer recurrence
2016	National Institute for Health and Care Excellence (NICE)	Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer. NICE technology appraisal guidance 403
2016	Canary Health Service	[Prognostic genomic tests for localized prostate cancer]
2016	NIHR Health Technology Assessment programme	Prediction of risk of recurrence of venous thromboembolism following treatment for a first unprovoked venous thromboembolism: systematic review, prognostic model and clinical decision rule, and economic evaluation
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Zoptarelin doxorubicin - endometrial cancer: locally advanced, recurrent or metastatic – second line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Cryoablation for the treatment of kidney tumors
2016	National Institute for Health and Care Excellence (NICE)	Degarelix for treating advanced hormone-dependent prostate cancer. NICE technology appraisal guidance 404
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Volanesorsen - familial chylomicronemia syndrome – first line
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Rituximab biosimilars
2016	National Institute for Health and Care Excellence (NICE)	Trifluridine-tipiracil for previously treated metastatic colorectal cancer. NICE technology appraisal guidance 405
2016	NIHR Health Technology Assessment programme	A systematic review, evidence synthesis and meta-analysis of quantitative and qualitative studies evaluating the clinical effectiveness, the cost-effectiveness, safety and acceptability of interventions to prevent postnatal depression
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Simtuzumab - liver fibrosis secondary to non-alcoholic steatohepatitis or primary sclerosing cholangitis
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Biomedical treatment for autism spectrum disorders
2016	Canadian Agency for Drugs and Technologies in Health (CADTH)	Anti-vascular endothelial growth factor drugs for the treatment of retinal conditions
2016	National Institute for Health and Care Excellence (NICE)	Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. NICE technology appraisal guidance 406
2016	NIHR Horizon Scanning Centre (NIHR HSC)	Teduglutide (Revestive) - short bowel syndrome: in paediatric patients aged 1-17 years who are dependent on parenteral nutrition
2016	Institute for Clinical Effectiveness and Health Policy (IECS)	Use of anti-neuronal antibodies to diagnose paraneoplastic neurological syndromes